A Study of QLS31905 in Patients With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

1. Written informed consent.

2. ≥18 years.

3. Female or male.

4. ECOG performance status score 0 or 1.

5. Histologically or cytologically confirmed diagnosis of advanced solid tumors.

6. Adequate haematological, hepatic and renal function.

Exclusion Criteria:

1. Any anticancer therapy or immunotherapy within 4 weeks prior to the start of study treatment.

2. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.

3. Patients with a history of monoclonal antibody allergic reaction.

4. Known human immunodeficiency virus infection or known symptomatic hepatitis.